Home
Products & Services
Support
About
Contact Us
FinancialContent is the trusted provider of stock market information to the media industry.
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Applied Genetic Tech (NQ: AGTC)
5.640 USD  -0.080 (-1.40%)
Official Closing Price  /  Updated: 6:18 PM EDT, Aug 12, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 136,843
Open 5.750
Bid (Size) 5.650 (2)
Ask (Size) 6.000 (38)
Prev. Close 5.720
Today's Range 5.560 - 5.770
52wk Range 2.290 - 10.42
Shares Outstanding 18,110,536
Dividend Yield N/A
Performance
YTD
+35.90%
+35.90%
1 Month
+0.18%
+0.18%
3 Month
+24.23%
+24.23%
6 Month
+9.73%
+9.73%
1 Year
+53.26%
+53.26%
Top News
More News
AGTC Formalizes Patient Advisory Council to Provide Insights and Guidance on Patient Perspectives for Pipeline Therapies
from GlobeNewswire News Releases
AGTC to Present at the Wedbush PacGrow Virtual Healthcare Conference on August 11, 2020
from GlobeNewswire News Releases
More News
Read More
AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase 2/3 Trial
from GlobeNewswire News Releases
AGTC Set to Join Russell 3000® and 2000® Indexes
from GlobeNewswire News Releases
AGTC Announces Significant Productivity and Quality Enhancement To Its Proprietary Manufacturing Process
from GlobeNewswire News Releases
AGTC to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference on June 23, 2020
from GlobeNewswire News Releases
Bionic Sight, LLC Doses First Patient in a Phase 1/2 Clinical Trial of a New Investigational Treatment for Blindness caused by Retinitis Pigmentosa
from GlobeNewswire News Releases
AGTC Launches Nationwide Mobile Vision Testing Program for Patients Enrolled in Its Ongoing Phase 1/2 Clinical Trials
from GlobeNewswire News Releases
AGTC Announces Publication of Positive Preclinical Data that Provides Foundational Scientific Evidence for its Ongoing Clinical Program in Patients with X-Linked Retinitis Pigmentosa (XLRP)
from GlobeNewswire News Releases
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2020
from GlobeNewswire News Releases
Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program
from GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
   
© Copyright FinancialContent Services, Inc.